Facial basal cell carcinoma: A retrospective study of 67 cases

Table 1 Relationship of the clinical type of basal cell carcinoma with age, gender, duration, and site of the lesion in 67 patients, n (%)

Variable	Clinical type							P value
	Pigmented		Noduloulcerative		Multifocal superficial		Total
Age groups per years								0.278
≤ 60	11 (47.8)	10 (43.5)		2 (8.7)		23 (100)
> 60	13 (29.5)	23 (52.3)		8 (18.2)		44 (100)
Total	24 (35.8)	33 (49.3)		10 (14.9)		67 (100)
Gender								0.691
Male	13 (33.3)	19 (48.7)		7 (18)		39 (100)
Female	11 (39.3)	14 (50)		3 (10.7)		28 (100)
Total	24 (35.8)	33 (49.3)		10 (14.9)		67 (100)
Duration per months								0.710
< 6	15 (32.6)	24 (52.2)		7 (15.2)		46 (100)
≥ 6	9 (42.9)	9 (42.9)		3 (14.2)		21 (100)
Total	24 (35.8)	33 (49.3)		10 (14.9)		67 (100)
Site								0.605
Nose	10 (50)	7 (35)		3 (15)		20 (100)
Eyelid	4 (44.4)	5 (55.6)		0		9 (100)
Forehead	5 (31.3)	9 (56.2)		2 (12.5)		16 (100)
Scalp	3 (30)	5 (50)		2 (20)		10 (100)
Cheek	2 (16.7)	7 (58.3)		3 (25)		12 (100)
Total	24 (35.8)	33 (49.3)		10 (14.9)		67 (100)

Table 2 Relationship of the histopathological type of basal cell carcinoma with age, gender, duration, and site of the lesion in 67 patients, n (%)

Variable	Histopathological type					P value
	Solid	Adenoid	Mixed	Keratotic	Total
Age groups per years						0.007
≤ 60	15 (65.2)	2 (8.7)	2 (8.7)	4 (17.4)	23 (100)
> 60	12 (27.3)	17 (38.6)	10 (22.7)	5 (11.4)	44 (100)
Total	27 (40.3)	19 (28.4)	12 (17.9)	9 (13.4)	67 (100)
Gender						0.952
Male	15 (38.5)	11 (28.2)	7 (17.9)	6 (15.4)	39 (100)
Female	12 (42.9)	8 (28.6)	5 (17.9)	3 (10.7)	28 (100)
Total	27 (40.3)	19 (28.4)	12 (17.9)	9 (13.4)	67 (100)
Duration per months						0.955
< 6	19 (41.3)	13 (28.3)	8 (17.4)	6 (13)	46 (100)
≥ 6	8 (38.1)	6 (28.6)	4 (19)	3 (14.3)	21 (100)
Total	27 (40.3)	19 (28.4)	12 (17.9)	9 (13.4)	67 (100)
Site						0.985
Nose	8 (40)	5 (25)	4 (20)	3 (15)	20 (100)
Eyelid	4 (44.4)	2 (22.2)	1 (11.2)	2 (22.2)	9 (100)
Forehead	7 (43.8)	5 (31.3)	3 (18.8)	1 (6.3)	16 (100)
Scalp	5 (50)	2 (20)	2 (20)	1 (10)	10 (100)
Cheek	3 (25)	5 (41.6)	2 (16.7)	2 (16.7)	12 (100)
Total	27 (40.3)	19 (28.4)	12 (17.9)	9 (13.4)	67 (100)

Table 3 Complications of diode laser ablation in the 67 patients with facial basal cell carcinoma

Complication	Frequency	Percentage
Bleeding at the bed lesion	1	1.5
Postoperative pain	10	14.9
Redness at the periphery of the ablated area	2	3
Mild edema	1	1.5
Postoperative infection	0	0